This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| NGF | |
|---|---|
| Name | Nerve growth factor |
| Organism | Homo sapiens |
| Gene | NGF |
| Length | 241 aa (prepro-NGF) |
| Location | Chromosome 1 |
NGF
Nerve growth factor (commonly abbreviated NGF) is a secreted peptide that belongs to the neurotrophin family and plays a central role in the survival, maintenance, and differentiation of specific neuronal populations. Discovered in pioneering work that connected cell biology with developmental neuroanatomy, NGF has been studied across model organisms and clinical contexts from Santiago Ramón y Cajal-inspired neuroanatomy to modern molecular neuroscience in institutions such as Cold Spring Harbor Laboratory and Max Planck Institute. NGF has been implicated in pathways studied by investigators at Harvard Medical School, Stanford University School of Medicine, University of Cambridge, and pharmaceutical research at Pfizer and Roche.
NGF was first characterized in classic experiments by researchers affiliated with Rockefeller University and later developed into a molecular concept by teams at Columbia University and University College London. The protein is produced as a precursor (prepro-NGF) and processed to a biologically active mature form; its discovery intersected with work on other trophic factors by labs at Yale University and Massachusetts Institute of Technology. NGF research connects to clinical neurology services at centers such as Mayo Clinic and Johns Hopkins Hospital, where its roles in neurodegeneration and pain are clinically relevant. Seminal reviews appeared in venues including Nature, Science, and Proceedings of the National Academy of Sciences.
The NGF gene resides on Chromosome 1 (human). Translation produces a prepro-peptide that undergoes signal peptide cleavage and endoproteolytic processing in the secretory pathway; endoproteases studied at The Scripps Research Institute participate in maturation. Mature NGF is a non-covalent dimer of ~13 kDa monomers and shares tertiary features with other neurotrophins characterized by structural studies at European Molecular Biology Laboratory and Brookhaven National Laboratory. High-resolution structures determined by groups at EMBL-EBI and Cold Spring Harbor Laboratory revealed the fold that mediates receptor binding to members of the neurotrophin receptor family. Biosynthesis and intracellular trafficking involve organelles studied in cell biology at Max Planck Institute for Biochemistry and Johns Hopkins University School of Medicine.
NGF primarily binds two classes of receptors: the high-affinity tyrosine kinase receptor TrkA (encoded by NTRK1) and the low-affinity p75 neurotrophin receptor (p75NTR). TrkA signaling activates canonical cascades including the Ras–MAPK pathway explored in work at University of California, Berkeley, the PI3K–Akt pathway studied at University of Pennsylvania, and PLCγ signaling examined by investigators at Imperial College London. p75NTR engages adaptors and crosstalk with death domain signaling characterized by studies at UCSF and Karolinska Institutet, modulating outcomes such as apoptosis or neurite outgrowth depending on cellular context. Downstream transcriptional responses involve factors characterized in molecular genetics work at Cold Spring Harbor Laboratory and National Institutes of Health laboratories.
NGF supports survival of sympathetic and certain sensory neurons in the peripheral nervous system, with foundational physiological studies performed at Columbia University and Rockefeller University. In the central nervous system, NGF influences cholinergic neuron maintenance in basal forebrain nuclei studied at University College London and King's College London. NGF regulates axonal guidance and synaptic maintenance; these roles were elaborated by groups at University of Oxford and University of California, San Diego. NGF also modulates non-neuronal cells: immune interactions investigated at Pasteur Institute and inflammatory studies at Cleveland Clinic reveal roles in mast cell activation and cytokine networks described in publications in The Lancet and Journal of Clinical Investigation.
During embryogenesis, NGF gradients direct survival and target innervation of sympathetic neurons in paradigms established at University of Chicago and Duke University School of Medicine. Postnatally, NGF participates in activity-dependent plasticity, learning, and memory processes examined by laboratories at MIT and Princeton University. Injury-induced expression changes in NGF have been documented in spinal cord repair studies at Karolinska Institutet and peripheral nerve regeneration work at Johns Hopkins Hospital. Synaptic remodeling and long-term potentiation modulation linked to NGF were reported from research groups at Columbia University Irving Medical Center and Yale School of Medicine.
Alterations in NGF signaling are implicated in neuropathic pain syndromes evaluated in clinical trials at Mayo Clinic and Cleveland Clinic Foundation, neurodegenerative disorders such as Alzheimer's disease studied intensively at Columbia University, Massachusetts General Hospital, and Alzheimer's Association-supported centers, and congenital insensitivity to pain with anhidrosis linked to mutations in the TrkA pathway investigated at NIH Clinical Center. NGF dysregulation appears in inflammatory diseases researched at University of Barcelona and oncology contexts where tumor microenvironment studies at Memorial Sloan Kettering Cancer Center examine trophic factor interactions. Biomarker studies have been reported in journals associated with American Neurological Association conferences.
Therapeutic strategies include recombinant NGF delivery, small molecules targeting TrkA developed by pharmaceutical teams at GlaxoSmithKline and Novartis, and monoclonal antibodies against NGF tested in multicenter trials led by groups at Mayo Clinic and Cleveland Clinic. Anti-NGF antibodies progressed through phase II/III pain trials coordinated with regulatory agencies such as European Medicines Agency and U.S. Food and Drug Administration. Gene therapy and viral vector approaches leveraging expertise from University of Pennsylvania and Stanford University are under investigation for neurodegeneration. Ongoing basic science at institutes like Salk Institute and translational programs at Howard Hughes Medical Institute continue to map receptor-specific effects to guide safer, targeted interventions.
Category:Proteins